| 11 |
Role of immunohistochemistry in molecular classification, prognosis, and survival of colorectal cancer patients |
2025 |
| 12 |
Prognostic significance of the tumor budding and tumor-infiltrating lymphocytes in survival of hepatocellular carcinoma patients |
2024 |
| 13 |
Assessment of Response to Hormonal Therapy by Serum Ki-67 as a Biomarker in Non-metastatic Hormone Positive Breast Cancer |
2024 |
| 14 |
Outcome of Anthracycline versus Taxane Based Regimens on Different Metastatic Sites in Breast Cancer |
2024 |
| 15 |
prognostic significance of the tumor budding and tumor- infiltrating lymphocytes in survival of hepatocellular carcinoma patients |
2024 |
| 16 |
Prognostic Value of Erythropoietin-Producing Hepatocellular Receptor A2 (Epha2) Serum Marker in Colorectal Cancer |
2024 |
| 17 |
Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line |
2024 |
| 18 |
The transcription factor ZEB-1 conveys chemoresistance in breast cancer |
2024 |
| 19 |
CD44 as a prognostic marker in early colorectal cancer: single center experience “South Egypt cancer institute”, Egypt |
2023 |
| 20 |
FOS-Like Antigen 1 Expression Was Associated With Survival of Hepatocellular Carcinoma Patients |
2023 |
